StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Total gross-to-net provisions & variable consideration by Quarter

Total gross-to-net (GTN) provisions & variable consideration deductions ($M) ($M)

QuarterlyAnnual

Moderna Total gross-to-net provisions & variable consideration: $28M in Q2 2026, down 54.8% from a year earlier.

Latest, Q2 2026
28
Period ended Jun 30, 2026
Change on a year earlier
-54.8%
62 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 2 (Gross-to-Net Rollforward).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal gross-to-net (GTN) provisions & variable consideration deductions ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202628-54.8%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 2026-2-110.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025407+101.5%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025998-12.8%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 202562+785.7%Form 10-Q (filed 2026-07-31) ↗
Q1 2025Mar 31, 202519-65.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024202-76.8%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 20241,144+72.5%Form 10-Q (filed 2025-11-06) ↗
Q2 2024Jun 30, 20247–Form 10-Q (filed 2025-08-01) ↗
Q1 2024Mar 31, 202455–Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023869–Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 2023663–Form 10-Q (filed 2024-11-07) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-01) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-02) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-21) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-03) ↗

Breakdown

What makes up total gross-to-net provisions & variable consideration

Cite this data

StockData. (2026). Moderna Total gross-to-net provisions & variable consideration ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/gtn-prov-total

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.